Canada's Minister of Health, Rona Ambrose, announced phase onefor the clinical trials of Canada's Ebola vaccine. The trial willbe led by the Canadian Immunization Research Network (CIRN) atHalifax, Nova Scotia, according to a press release.
|“Canada's experimental Ebola vaccine is the result of years ofresearch and hard work by Canadian scientists. The results of thisclinical trial will offer us valuable data about the safety andeffectiveness of our vaccine and will hopefully provide us with theinformation we need to proceed with further clinical trials in thecountries most affected by Ebola,” said Dr. Gregory Taylor,Chief Public Health Officer of Canada.
|This first trial will test the experimental vaccine on a smallgroup of people to assess its safety, dosage and possible sideeffects. The trial is jointly funded by the Canadian Institutes ofHealth Research (CIHR) and the Public Health Agency of Canada(PHAC). The vaccine does not contain a live Ebola virus and thereis no risk that the volunteers could contract the virus throughthese trials, says the press release.
|Canada joins the trials being carried out at the Walter ReedArmy Institute of Research in Silver Spring, Maryland and at theNational Institutes of Health in Bethesda, Maryland. The Canadiantrial will examine lower dosing levels as well as the effect of thevaccine on older populations.
|See also:
|Ebola's economic impact confined to WestAfrica, Goldman says
|Want to continue reading?
Become a Free PropertyCasualty360 Digital Reader
Your access to unlimited PropertyCasualty360 content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- All PropertyCasualty360.com news coverage, best practices, and in-depth analysis.
- Educational webcasts, resources from industry leaders, and informative newsletters.
- Other award-winning websites including BenefitsPRO.com and ThinkAdvisor.com.
Already have an account? Sign In
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
